Ginkgo Bioworks Holdings, Inc. DNA NYSE

Ginkgo Bioworks Holdings, Inc. (DNA) generated $-171.06M in operating cash flow for fiscal year 2025. After capital expenditures of $7.67M, free cash flow was $-178.72M.

Free cash flow margin was -105% of revenue. Cash conversion ratio was 0.55x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (75/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (58/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 0.55x suggests some earnings are non-cash items

Overall SharesGrow Score: 45/100 with 2/7 criteria passed.